

ORIGINAL CONTRIBUTIONS

Histology and Cytochemistry of Human Skin <i>Robert L. Dimond, MD, William Montagna, PhD, Beaverton, Ore</i>	1235
Tachyphylaxis to Topically Applied Steroids <i>Anthony du Vivier, MB, MRCP, La Jolla, Calif</i>	1245
Ultraviolet Light and Tar in the Goeckerman Treatment of Psoriasis <i>Albert R. Marsico, MD; William H. Eaglstein, MD; Gerald D. Weinstein, MD, Miami</i>	1249
Lichen Planus Subtropicus <i>Mouta Dilaimy, MD, Baltimore</i>	1251
Atopic Dermatitis and IgE <i>Stephen P. Stone, MD; Gerald J. Gleich, MD; Sigfrid A. Muller, MD, Rochester, Minn</i>	1254
Noninflammatory Destruction of Actinic Keratoses by Fluorouracil <i>Thomas Breza, MD; J. Richard Taylor, MD; William H. Eaglstein, MD, Miami</i>	1256
CASE REPORTS	
Skin Lesions Induced by Penicillamine <i>Kenneth E. Greer, MD; Fletcher C. Askew, MD; Donald R. Richardson, MD, Charlottesville, Va</i>	1267
Xanthelasma <i>James E. Rasmussen, MD, Buffalo, NY</i>	1270
Relapsing Polychondritis Treated With Dapsone <i>John Martin, MD; Henry H. Roenigk, Jr, MD; William Lynch, MD; Fred R. Tingwald, MD, Cleveland</i>	1272
Staphylococcal Scalded Skin Syndrome in an Adult and a Child <i>Stephen W. Sturman, MD, Frederick D. Malkinson, MD, DMD, Chicago</i>	1275
Lichen Planus Pemphigoides <i>Stuart Sobel, MD; Robert Miller, MD; Harry Shatin, MD, New York</i>	1280
Nevus of Ota With Ipsilateral Congenital Cataract <i>Garry B. Gewirtzman, MD, James E. Rasmussen, MD, Buffalo, NY</i>	1284
Treatment of Relapsing Polychondritis With Dapsone <i>Vincent P. Barranco, MD; Dwane B. Minor, MD, Tulsa, Okla; Herman Solomon, MD, Wichita, Kans</i>	1286
Immediate Hypersensitivity In Hand Dermatitis <i>Howard Maibach, MD, San Francisco</i>	1289
Simultaneous Systemic Lupus Erythematosus and Dermatitis Herpetiformis <i>Michael Glanmor Davis, BSc, MB, ChB, MRCP; Ronald Marks, MB, BSc, MRCP; Eric Waddington, MD, FRCP, Cardiff, Wales</i>	1292
Epithelioma Cuniculatum <i>Stuart M. Brown, MD, Robert G. Freeman, MD, Dallas</i>	1295

(Continued on page 1204)

EDITORIAL BOARD

Chief Editor
John H. Epstein, MD
450 Sutter Street
San Francisco 94108

Assistant Chief Editor
Kimie Fukuyama, MD
San Francisco

Assistant Chief Editor
Denny L. Tuffanelli, MD
San Francisco

Donald C. Abele, MD
Augusta, Ga

Harry L. Arnold, Jr., MD
Honolulu

Walter C. Lobitz, Jr., MD
Portland, Ore

Frederick D. Malkinson, MD
Chicago

Sigfrid A. Muller, MD
Rochester, Minn

W. Mitchell Sams, Jr., MD
Denver

John S. Strauss, MD
Boston

Morris Waisman, MD
Tampa, Fla

Gerald D. Weinstein, MD
Miami

CONTENTS—Continued

Pyoderma Gangrenosum Associated With Active Chronic Hepatitis
James P. H. Byrne, MA, MB, MRCP (I), MRCP (UK), Stoke-on-Trent, England; Mark Hewitt, MD, FRCP, Cornwall and Isles of Scilly Area Health Authority; Roy Summerly, MB, FRCP, FRCP (Edin), Stoke-on-Trent, England 1297

Cutaneous Extramedullary Hematopoiesis
Tseng-tong Kuo, MD, PhD; John Uhlemann, MD; Edward H. Reinhard, MD, St Louis 1302

Acrodermatitis Enteropathica
William S. Lynch, MD, Henry H. Roenigk, Jr, MD, Cleveland 1304

Pemphigus in a Patient Treated With Penicillamine for Generalized Morphea
Michael G. Davies, BSc, MB, ChB, MRCP, Peter Holt, MB, ChB, MRCP, Cardiff, Wales 1308

Acquired Generalized Anhidrosis
Takuo Tsuji, MD, PhD, Tetsuo Yamamoto, MD, Osaka, Japan 1310

REGULAR DEPARTMENTS

Letters to the Editor 1323

Biting Insect Summary Claude A. Frazier, MD, Asheville, NC . . . **Observations on "EngLat" Language: Nevus Sebaceous or Nevus Sebaceus** Harry L. Arnold, Jr, MD, Honolulu . . . **Chlorpromazine and Drug Eruptions** Takeshi Horio, MD, Kyoto, Japan . . . **Purpuric Reactions Following Dermabrasion** W. Edward Dalton, MD, Paul Silverstein, MD, Oklahoma City . . . **Clindamycin Therapy for Moderately Severe Acne** John M. Siegel, MD, Newport Beach, Calif; Richard A. Finley, MD, Johnson City, NY; Gerald G. Krueger, MD, Grant L. Christian, MD, Salt Lake City . . . **Melanoma** Milton R. Okun, MD, Boston . . . **Scabies in Malaysia** John H. S. Pettit, MD, FRCP, Kuala Lumpur, Malaysia . . . **Transfer Factor as Therapeutic Agent in Mycosis Fungoides** Hugh Zachariae, MD; Eva Grunnet, MD; Jørgen Ellegaard, MD; Kristian Thestrup-Pedersen, MD; Aarhus, Denmark . . . **Glaucoma From Topically Applied Steroids** Charles Zuger, MD; Donald Saunders, MD; Fred Levit, MD, Chicago . . . **Frequency of Skin Lesions in Chronic Drinkers** Jack Margolis, MD; Doris M. Roberts, RN, Big Spring, Tex . . . **Allopurinol-Caused Toxic Epidermal Necrolysis** Michael J. Fellner, MD, New York; Michael Eilman, MD; David F. Fretzin, MD, Chicago . . . **Long-Term Triamcinolone Acetonide Therapy** Harry L. Arnold, Jr, MD, Honolulu, CAPT Thomas E. Carson, MC, USN, Oakland, Calif . . . **Autoantibodies in Vitiligo** Corrado Betterle, MD; Gian Franco Del Prete, MD; Andrea Peserico, MD; Giorgio Bersani, MD; Franco Caracciolo, MD; Alberto Trisotto, MD, Padua, Italy; Flavio Poggi, MD, Ferrara, Italy . . . **Long-Term Intramuscular Administration of Triamcinolone Acetonide** Dale Pearlman, MD, Stanford, Calif, T. E. Carson, Oakland, Calif . . . **Condyloma Acuminata in Infants and Children** Leon Goldman, MD, Michael Feldman, MD, Stephen Levitt, MD, Cincinnati . . . **Antinuclear Antibodies in Lupus Erythematosus** Thomas K. Burnham, MB, BS, (London) Detroit

News and Notes 1333

Society Transactions 1339

Books 1346

Instructions for Authors 1208

Index to Advertisers 1354

SUBSCRIPTION RATES: The yearly rate of the ARCHIVES OF DERMATOLOGY is as follows: United States and US Possessions, one year, \$18; two years, \$28; all other countries, one year, \$28; two years, \$38. Special yearly price to residents, interns and medical students in the United States and US Possessions, \$9.

THE ARCHIVES OF DERMATOLOGY is published monthly by the American Medical Association, 535 N Dearborn St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage paid at Chicago and at additional mailing office.

DESCRIPTION

Synalar® (flucinolone acetonide) has the chemical name 6 α , 9 α -difluoro-16 α -hydroxyprednisolone-16, 17-acetonide.

Synalar® Solution 0.01%—contains 0.01% flucinolone acetonide in propylene glycol with citric acid.

Synalar® Ointment 0.025%—contains 0.025% flucinolone acetonide in white petrolatum.

Synalar-HP® Cream—contains 0.2% flucinolone acetonide in a water-washable aqueous base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan mono-stearate, polyoxyethylene sorbitan monostearate and citric acid, with methylparaben and propylparaben as preservatives.

Synemol™ (flucinolone acetonide) has the chemical name 6 α , 9 α -difluoro-16 α -hydroxyprednisolone-16, 17-acetonide.

The vehicle is a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan monostearate, polyoxyethylene sorbitan mono-stearate and citric acid.

INDICATIONS

For relief of the inflammatory manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical steroids are contraindicated in vaccinia and varicella.

Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Synalar-HP Cream should not be used on infants up to two years of age.

PRECAUTIONS

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

If extensive areas are treated or if the occlusive technique is used, the possibility exists of increased systemic absorption of the corticosteroid and suitable precautions should be taken.

Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their use in pregnant females has not absolutely been established. Therefore, they should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Topical steroids are not for ophthalmic use.

Synalar-HP Cream should not be used for prolonged periods and the quantity per day should not exceed 2 g of formulated material.

ADVERSE REACTIONS

The following local adverse reactions have been reported with topical corticosteroids: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation.

Synalar Cream and Ointment, Synemol Cream.

The following may occur more frequently with occlusive dressings than without such therapy: maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

HOW SUPPLIED

Synalar® (flucinolone acetonide)
 Cream 0.025%—15, 60 g tubes; 120, 425 g jars.
 Cream 0.01%—15, 45, 60 g tubes; 120, 425 g jars.
 Ointment 0.025%—15, 60 g tubes; 425 g jars.
 Solution 0.01%—20, 60 cc plastic squeeze bottles.
 Synalar-HP® (flucinolone acetonide) 0.2% Cream—5, 12 g tubes.
 Synemol™ (flucinolone acetonide)
 Cream 0.025%—15, 60 g tubes.

These preparations are available on prescription only.

SYNTEX
 SYNTEX LABORATORIES, INC.
 PALO ALTO, CALIFORNIA 94304